汉利康® (rituximab injection) is the Company's first proprietary product. It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with Technical Guidelines for the Development and Evaluation of Biosimilars (Tentative) for the treatment of 1) relapsed or refractory, follicular lymphoma; 2) previously untreated stages III-IV follicular, non-Hodgkin lymphoma; 3) CD20-positive, diffuse large B-cell, non-Hodgkin lymphoma; 4) chronic lymphocytic leukemia and 5) follicular lymphoma. Meanwhile, a differentiated strategy is adopted to fully develop its potential in rheumatoid arthritis (RA) and to benefit a broader patient population. The New Drug Application (NDA) for RA was accepted for review in December, 2020.

汉曲优^®(HLX02, trastuzumab injection, Zercepac^® in the EU) was successfully launched in China and Europe, becoming the first Chinese mAb biosimilar entering both the EU and China market. It is indicated for the treatment of 1) HER2 positive early breast cancer; 2) HER2 positive metastatic breast cancer and 3) HER2 positive metastatic gastric cancer, which corresponds to all the approved indications of the trastuzumab originator. 汉曲优^® is the first EU GMP-certificated Chinese mAb biosimilar. It will bring more treatment options to patients with HER2 positive breast and gastric cancer worldwide.